Maxim Reiterates Upbeat View Of StemCells Inc Following First Patient Dosed In Dry-AMD Phase 2
In a research report issued today, Maxim analyst Jason Kolbert reiterated a Buy rating on StemCells Inc (NASDAQ:STEM) with a $5.00 price target, after the company announced that the first patient in the Dry-AMD phase II study has been dosed using the company’s human neuronal stem cells (HuCNS-SC). Shares of StemCells closed today at $0.508, up $0.003 or 0.59%
Kolbert wrote, “First patient dosed is a milestone for the company and builds on data from the phase I/II study presented in June that was suggestive of an efficacy signal with zero safety issues. The latter cannot be over emphasized as we have seen other companies like Avalanche have unwanted side effects like thickening of the retina.”
The analyst continued, “STEM continues to make progress with the neuronal stem cell platform. In addition to Dry-AMD, the ongoing phase II “PATHWAY” study in cervical spinal cord injury could produce data later this year. We continue to believe that with capital raised and multiple data-drive catalysts that 2015 is a year of inflection for STEM.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 1.5% and a 42.7% success rate. Kolbert has a -47.6% average return when recommending STEM, and is ranked #1558 out of 3712 analysts.